ReviewJournal of intensive care medicine
Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
Review in Journal of intensive care medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 194 citations in OpenAlex.
- Clinical characteristics, management, and outcomes of cadmium poisoning: a systematic review of case reports and case series.Frontiers in public health · 2025Pooled it
- Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial.PloS one · 2014Trial
- Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome.Journal of thrombosis and haemostasis : JTH · 2013Trial
- Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury.Thorax · 2008Trial
- Randomized clinical trial of activated protein C for the treatment of acute lung injury.American journal of respiratory and critical care medicine · 2008Trial
- Sparstolonin B nano-formulation attenuates LPS-induced lung injury.Frontiers in pharmacology · 2025Article
- Inhaled Corticosteroids Use Before Hospitalization May Be Protective in Children With Direct Lung Injury.CHEST critical care · 2024Article
- Efficacy of CU06-1004 via regulation of inflammation and endothelial permeability in LPS-induced acute lung injury.Journal of inflammation (London, England) · 2023Article
- STING inhibitor ameliorates LPS-induced ALI by preventing vascular endothelial cells-mediated immune cells chemotaxis and adhesion.Acta pharmacologica Sinica · 2022Article
- New Insights into the Role of the Complement System in Human Viral Diseases.Biomolecules · 2022Review
- Pharmacologic therapies of ARDS: From natural herb to nanomedicine.Frontiers in pharmacology · 2022Review
- CXC Chemokines in the Pathogenesis of Pulmonary Disease and Pharmacological Relevance.International journal of inflammation · 2022Review
- Article
- Cisatracurium attenuates LPS-induced modulation of MMP3 and junctional protein expression in human microvascular endothelial cells.Bioscience trends · 2021Article
- The Effect of Exogenous Surfactant on Moderate and Severe Stages of COVID-19 Induced ARDS: the Pilot Study of a Clinical Trial.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed.Frontiers in microbiology · 2021Review
- MicroRNA-145 plays a role in mitochondrial dysfunction in alveolar epithelial cells in lipopolysaccharide-induced acute respiratory distress syndrome.World journal of emergency medicine · 2021Article
- COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Isolation, culture, and characterization of chicken lung-derived mesenchymal stem cells.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2018Article
- Effects of indole alkaloids from leaf of Alstonia scholaris on post-infectious cough in mice.Journal of ethnopharmacology · 2018Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Acute lung injury and the acute respiratory distress syndrome are common syndromes with a high mortality rate that affect both medical and surgical patients. Better understanding of the pathophysiology of acute lung injury and the acute respiratory distress syndrome and advances in supportive care and mechanical ventilation have led to improved clinical outcomes since the syndrome was first described in 1967. Although several promising pharmacological therapies, including surfactant, nitric oxide, glucocorticoids and lysofylline, have been studied in patients with acute lung injury and the acute respiratory distress syndrome, none of these pharmacological treatments reduced mortality. This article provides an overview of pharmacological therapies of acute lung injury and the acute respiratory distress syndrome tested in clinical trials and current recommendations for their use as well as a discussion of potential future pharmacological therapies including beta(2)-adrenergic agonist therapy, keratinocyte growth factor, and activated protein C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.